Dawn Svoronos - 05 Jun 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
05 Jun 2025
Net transactions value
$0
Form type
4
Filing time
06 Jun 2025, 17:57:25 UTC
Previous filing
23 May 2025
Next filing
20 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Svoronos Dawn Director 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 06 Jun 2025 0001574579

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Share Option (Right to Buy) Award $0 +17,012 $0.000000 17,012 05 Jun 2025 Common Shares 17,012 $30.73 Direct F1
transaction XENE Restricted Share Units Award $0 +2,645 $0.000000 2,645 05 Jun 2025 Common Shares 2,645 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.
F2 Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.